Transcend Medical, Inc.: Series B $16M

Posted in I - Series B, Q - 3Q11, R - WEST, X - Device (Ophthalmology), XX - CA

Transcend Medical (Menlo Park, CA) a clinical-stage medical device company focused on the treatment of glaucoma, closed a $16 Series B, bringing the total round to $51M. Participants include Investor Growth Capital, Canaan Partners, Finistere Ventures, HLM Venture Partners, Kaiser Permanente Ventures, Latterell Venture Partners, Morgenthaler Ventures, Split Rock Partners and Technology Partners.
Thanx for your [...]

Jan

2012

Second Genome, Inc.: Series A $5M

Posted in I - Series A, Q - 3Q11, R - WEST, X - CRO, X - Device (Diagnostic), X - Target ID, XX - CA

Second Genome (San Francisco, CA) a commercial-stage microbial profiling company designed to enable diagnostic/prognostic signatures and target identification, closed a $5M Series A financing. Participants include Advanced Technology Ventures, Morgenthaler Ventures, Wavepoint Ventures and Seraph Group.
Thanx for your patience as we catch-up.

Aug

2010

Calithera Biosciences, Inc.: Series A $40M

Posted in I - Series A, Q - 3Q10, R - WEST, X - Caspase, X - Oncology

Calithera Biosciences (San Francisco, CA) a preclinical-stage small molecule company focused on caspase activators for oncologic applications, closed a $40M Series A financing. Participants include Morgenthaler Ventures, U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital.

Jul

2010

Stemgent, Inc.: Series B $5.6M

Posted in I - Series B, Q - 2Q10, R - NORTH EAST, X - Reagent, X - Stem Cell, XX - MA

Stemgent (Cambridge, MA) a commercial-stage supplier of stemcell related reagents and tools, closed a $5.6M Series B financing. Participants include HealthCare Ventures and Morgenthaler Ventures.

Jun

2010

FoldRx Pharmaceutials, Inc.: Series C $29M

Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - Cardiology, X - Neuro Degenerative, X - Protein Folding, XX - MA

FoldRx Pharmaceuticals (Cambridge) a clinical-stage small molecule company focused on protein misfolding and aggregation in transthyretin amyloid polyneuropathy and other neurodegenerative and cardiovascular diseases, closed a $29M Series C financing. Participants include Novo Ventures, Morgenthaler Ventures, HealthCare Ventures, Fidelity Biosciences, TPG Biotech, Alta Partners and Novartis Venture Funds.

Apr

2010

GlobeImmune, Inc.: Series E $17.5M

Posted in I - Series E, Q - 1Q10, R - ROCKY MOUNTAIN, X - Hepatitis C, X - Oncology, X - Vaccines, XX - CO

GlobeImmune (Lousiville, CO) a clinical-stage biopharmaceutical company developing a therapeutic vaccine platform focused on pancreatic cancer and hepatitis C, Closed a $17.5M Series E financing. Participants include Generali Financial Holding, BSI, Celgene, Wexford Capital, Mellon Family Investment Company, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, Partners Healthcare, Yasuda, Genentech, Biogen Idec, CIDC, PAC-LINK [...]

Mar

2010

Promedior, Inc.: Series C $12M

Posted in I - Series C, Q - 1Q10, R - NORTH EAST, X - Fibrosis, X - Inflammation, XX - PA

Promedior (Malvern, PA) a clinical-stage biopharmaceutical company focused on inflammation and fibrotic disease, closed a $12M Series C financing. Participants include Forbion Capital Partners, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners and Easton Capital.

to top of page...